Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports
In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...
Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli ...
We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...
Eli Lilly rises 6.3%
Eli Lilly (LLY) is up 6.3%, or $48.00 to $805.54.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
Seeking Alpha5 天
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
Reuters has earlier reported that two copies of Novo's weight-loss and diabetes drugs, Orsema and Fitaro, had been approved ...
24/7 Wall St3 天
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...